Skip to main content
Clinical Trials/JPRN-UMIN000021305
JPRN-UMIN000021305
Recruiting
Phase 2

Phase II clinical trial of Gemcitabine and Nab-Pacritaxel combined therapy for pancreatic cancer with the difficulty of curative resection - Phase II clinical trial of Gemcitabine and Nab-Pacritaxel combined therapy for pancreatic cancer with the difficulty of curative resection

Department of Surgery, Tohoku University Graduate School of Medicine0 sites60 target enrollmentMarch 7, 2016

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Pancreatic cancer
Sponsor
Department of Surgery, Tohoku University Graduate School of Medicine
Enrollment
60
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 7, 2016
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Surgery, Tohoku University Graduate School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\) not diagnosed as pancreatic duct adenocarcinoma (2\) recurrence (3\) obvious distant metastasis (4\) with prior anticancer therapy for pancreatic cancer (5\) with other active cancer (6\) with uncontrollable infection (7\) with hypersensitivity for pacritaxel or albmin (8\) pregnancy, postpartum within 28 days or lactating (9\) expected survival within 6 months (10\) difficult for out patient chemotherapy (11\) age \< 20 (12\) without judgement (13\) determined to be inappropriate as a subject

Outcomes

Primary Outcomes

Not specified

Similar Trials